Sumitomo Pharma Statistics
Total Valuation
Sumitomo Pharma has a market cap or net worth of 6.24 billion. The enterprise value is 7.68 billion.
| Market Cap | 6.24B |
| Enterprise Value | 7.68B |
Important Dates
The next estimated earnings date is Friday, January 30, 2026.
| Earnings Date | Jan 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 397.29M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 0.04% |
| Owned by Institutions (%) | 15.68% |
| Float | 183.27M |
Valuation Ratios
The trailing PE ratio is 5.97.
| PE Ratio | 5.97 |
| Forward PE | n/a |
| PS Ratio | 2.07 |
| PB Ratio | 3.48 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 40.12 |
| P/OCF Ratio | 30.81 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.60, with an EV/FCF ratio of 49.40.
| EV / Earnings | 7.35 |
| EV / Sales | 2.68 |
| EV / EBITDA | 8.60 |
| EV / EBIT | 10.25 |
| EV / FCF | 49.40 |
Financial Position
The company has a current ratio of 1.36, with a Debt / Equity ratio of 0.99.
| Current Ratio | 1.36 |
| Quick Ratio | 0.83 |
| Debt / Equity | 0.99 |
| Debt / EBITDA | 1.89 |
| Debt / FCF | 11.42 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 81.47% and return on invested capital (ROIC) is 14.15%.
| Return on Equity (ROE) | 81.47% |
| Return on Assets (ROA) | 9.25% |
| Return on Invested Capital (ROIC) | 14.15% |
| Return on Capital Employed (ROCE) | 20.16% |
| Revenue Per Employee | 785,064 |
| Profits Per Employee | 272,835 |
| Employee Count | 3,832 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 1.81 |
Taxes
| Income Tax | -80.44M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +340.40% in the last 52 weeks. The beta is 0.54, so Sumitomo Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | +340.40% |
| 50-Day Moving Average | 6.73 |
| 200-Day Moving Average | 10.41 |
| Relative Strength Index (RSI) | 79.95 |
| Average Volume (20 Days) | 1,547 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sumitomo Pharma had revenue of 3.01 billion and earned 1.05 billion in profits. Earnings per share was 2.63.
| Revenue | 3.01B |
| Gross Profit | 1.85B |
| Operating Income | 789.34M |
| Pretax Income | 965.06M |
| Net Income | 1.05B |
| EBITDA | 940.39M |
| EBIT | 789.34M |
| Earnings Per Share (EPS) | 2.63 |
Balance Sheet
The company has 260.09 million in cash and 1.78 billion in debt, giving a net cash position of -1.52 billion.
| Cash & Cash Equivalents | 260.09M |
| Total Debt | 1.78B |
| Net Cash | -1.52B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 1.79B |
| Book Value Per Share | 4.52 |
| Working Capital | 487.06M |
Cash Flow
In the last 12 months, operating cash flow was 202.54 million and capital expenditures -47.00 million, giving a free cash flow of 155.54 million.
| Operating Cash Flow | 202.54M |
| Capital Expenditures | -47.00M |
| Free Cash Flow | 155.54M |
| FCF Per Share | n/a |
Margins
Gross margin is 61.63%, with operating and profit margins of 26.24% and 34.75%.
| Gross Margin | 61.63% |
| Operating Margin | 26.24% |
| Pretax Margin | 32.08% |
| Profit Margin | 34.75% |
| EBITDA Margin | 31.26% |
| EBIT Margin | 26.24% |
| FCF Margin | 5.17% |
Dividends & Yields
Sumitomo Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 0.00% |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 16.76% |
| FCF Yield | 2.49% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sumitomo Pharma has an Altman Z-Score of 1.84 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.84 |
| Piotroski F-Score | 6 |